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Abstract 
Background: Drug resistance is one of the greatest challenges of malaria control programme in Mali. Recent 
advances in next-generation sequencing (NGS) technologies provide new and effective ways of tracking drug-resist-
ant malaria parasites in Africa. The diversity and the prevalence of Plasmodium falciparum drug-resistance molecular 
markers were assessed in Dangassa and Nioro-du-Sahel in Mali, two sites with distinct malaria transmission patterns. 
Dangassa has an intense seasonal malaria transmission, whereas Nioro-du-Sahel has an unstable and short seasonal 
malaria transmission.
Methods: Up to 270 dried blood spot samples (214 in Dangassa and 56 in Nioro-du-Sahel) were collected from P. fal-
ciparum positive patients in 2016. Samples were analysed on the Agena MassARRAY ® iPLEX platform. Specific codons 
were targeted in Pfcrt, Pfmdr1, Pfdhfr, and Pfdhps, Pfarps10, Pfferredoxin, Pfexonuclease and Pfmdr2 genes. The Sanger’s 
101-SNPs-barcode method was used to assess the genetic diversity of P. falciparum and to determine the parasite 
species.
Results: The Pfcrt_76T chloroquine-resistance genotype was found at a rate of 64.4% in Dangassa and 45.2% in 
Nioro-du-Sahel (p = 0.025). The Pfdhfr_51I-59R-108N pyrimethamine-resistance genotype was 14.1% and 19.6%, 
respectively in Dangassa and Nioro-du-Sahel. Mutations in the Pfdhps_S436-A437-K540-A581-613A sulfadoxine-resist-
ance gene was significantly more prevalent in Dangassa as compared to Nioro-du-Sahel (p = 0.035). Up to 17.8% of 
the isolates from Dangassa vs 7% from Nioro-du-Sahel harboured at least two codon substitutions in this haplotype. 
The amodiaquine-resistance Pfmdr1_N86Y mutation was identified in only three samples (two in Dangassa and one 
in Nioro-du-Sahel). The lumefantrine-reduced susceptibility Pfmdr1_Y184F mutation was found in 39.9% and 48.2% 
of samples in Dangassa and Nioro-du-Sahel, respectively. One piperaquine-resistance Exo_E415G mutation was 
found in Dangassa, while no artemisinin resistance genetic-background were identified. A high P. falciparum diversity 
was observed, but no clear genetic aggregation was found at either study sites. Higher multiplicity of infection was 
observed in Dangassa with both COIL (p = 0.04) and Real McCOIL (p = 0.02) methods relative to Nioro-du-Sahel.
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Background
Despite numerous advances in malaria control strate-
gies, the disease still kills countless children worldwide, 
mainly in sub-Saharan African countries. The World 
Health Organization (WHO) reported no significant 
progress in reducing global malaria burden during the 
period from 2015 to 2017 [1]. In Mali, as well as in the 
rest of the world, resistance to anti-malarial drugs is one 
of the greatest challenges of the National Malaria Control 
Programme (NMCP) [2, 3]. High prevalence of resistance 
to chloroquine and sulfadoxine-pyrimethamine (SP) led 
the Malian NMCP to switch to artemisinin- based com-
bination therapy (ACT) in the 2000s, as recommended by 
the WHO [4]. Artemisinin and its derivative drugs (Arte-
misinins) are still very effective in Africa [5, 6]. Resistance 
to these drugs have been reported in East-Asia [7, 8]. One 
of the rationales of ACT use is to maintain long-term 
efficacy of artemisinins to P. falciparum [4]. To achieve 
this objective, the choice of the artemisinin partner drugs 
is important and should be made based on their effec-
tiveness on circulating local parasite isolates. Conse-
quently, it appears important to monitor the emergence 
and spread of the anti-malarial drug resistance in differ-
ent geographical and endemic areas in order to inform 
the choice of the anti-malarial molecules to be associ-
ated with artemisinins in ACT [9, 10]. Also, assessing the 
genetic diversity of P. falciparum populations in different 
regions may allow to tract malaria parasites circulating 
across different geographic areas.
Molecular markers of drug-resistance are very useful in 
identifying drug-resistant P. falciparum. They are used in 
epidemiological surveillance of drug-resistance includ-
ing their emergence and spread monitoring. Molecular 
markers have been described for many of the common 
anti-malarial drug and are constituted of either sin-
gle nucleotide substitution (SNP) or concatenated SNP 
in genes involved in parasite interaction with drugs. 
Evidence of association between several alleles in P. 
falciparum multi-drug resistance (Pfmdr) gene and chlo-
roquine-resistance was reported in 1990 [11]. However, 
the K76T mutation in P. falciparum chloroquine resist-
ance transporter gene (Pfcrt_K76T) mostly associated 
with the Pfcrt_72C-73V-74I-75E-76T haplotype in Africa 
is known as the strongest chloroquine-resistance marker 
in P. falciparum [12–15]. Resistance to pyrimethamine 
has also been associated with numbers of mutations 
combination in the P. falciparum dihydrofolate-reduc-
tase (Pfdhfr) gene, such as the Pfdhfr_51I-59R-164L [16] 
and Pfdhfr_51R-59N-108I genotypes [17, 18]. Also vari-
ous combinations of substitutions at the codons 436, 
437, 540, 581 and 613 of the P. falciparum dihydropter-
oate-synthetase (Pfdhps) gene may confer resistance to 
sulfadoxine [19]. The greater the number of substitu-
tion accumulation is in the gene, the more the parasite 
gets resistant to the sulfadoxine. The Pfdhps_437G-540E 
genotype was associated with substantially decreased 
susceptibility to sulfadoxine. In  vitro experiments have 
shown that N86Y mutation in the P. falciparum multid-
rug resistance-1 (Pfmdr1) gene (Pfmdr1_86Y) increases 
the fifty percent inhibitory concentrations (IC50) of chlo-
roquine and amodiaquine [20, 21].
Mutations in multidrug resistance protein (pfmdr1) 
have been associated with various parasite response 
to mefloquine and lumefantrine [22]. Reduced suscep-
tibility to lumefantrine has been associated with the 
Pfmdr1_Y184F mutation [23–25]. In a recent genome-
wide association study (GWAS), the E415G mutation, a 
SNP in P. falciparum exonuclease gene (Pfexo_E415G)) 
was associated with ex  vivo piperaquine IC50 of para-
site isolates from Cambodia [26]. The co-inheritance of 
several mutations in P. falciparum Apicoplast Ribosomal 
Protein S10 (Pfarps10) gene [Pfarps10_127M-128Y/H], 
the P. falciparum ferredoxin (PfFd) gene [Pffd_ 193Y], 
the PfCRT gene: [Pfcrt_326S-356T], and the PfMDR2 
[Pfmdr2_T484I] were shown to constitute a genetic back-
ground that allows for the emergence of mutations in the 
P. falciparum kelch 13 gene [27], a known artemisinin 
resistance locus [28–30]. This haplotype is referred to as 
artemisinin-resistant parasite genetic background (Art-
resistant PGB).
All thought previous studies has provided insights into 
some anti-malarial drug resistance markers in the south 
of Mali [31, 32], the risk of P. falciparum infection is vari-
able from south (with intense and long transmission) to 
north (with unstable and short transmission) in Mali. 
This variability is related to environmental and climatic 
conditions. The level of transmission may also impact 
the malaria parasite genetic diversity and the spread of 
resistance to anti-malarial drugs. In fact, the higher the 
malaria transmission is, the more diverse the parasite 
population is, the more likely the parasite gets resistant 
to anti-malarial drugs.
Conclusions: This study reveals high prevalence of chloroquine and pyrimethamine-resistance markers as well as 
high codon substitution rate in the sulfadoxine-resistance gene. High genetic diversity of P. falciparum was observed. 
These observations suggest that the use of artemisinins is relevant in both Dangassa and Nioro-du-Sahel.
Keywords: Plasmodium falciparum, Drug-resistance, Molecular surveillance, Next-generation sequencing
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In this study, both the genetic diversity of P. falcipa-
rum and the distribution of drug resistance markers were 
assessed in two distinct eco-climatic areas in Mali.
Methods
Study sites
The epidemiology, entomology and the impact 
of malaria vary widely across the Malian terri-
tory [33, 34]. The study was carried out in Dangassa 
(Lat = 12.150,925, Long = − 8.206974) and Nioro-du-
Sahel (Lat = 15.224674, Long = − 9.583888). Dangassa 
is located in south savannah grassland of Mali along the 
right side of Niger River and has year-round access to 
water (Niger River). Malaria transmission is seasonal and 
mainly occurs from June to December. However, dry sea-
son transmission may occurs because of the Niger River. 
Indeed, mosquito breeding occurs primarily in micro-
habitats, such as the footprints of cattle and the reced-
ing river in the dry season, which leaves natural pools as 
well as man-made pools from river gold mining. Nioro-
du-Sahel is located in Sahelian region of Mali near the 
Islamic Republic of Mauritania. Malaria transmission 
is unstable and occurs from July to September. Anoph-
eles gambiae breeding sites are strictly rain-dependent. 
Anopheles gambiae (about 95%) and Anopheles arabien-
sis (about 5%) are the predominant malaria vectors [35] 
in the two sites. Population migration occurs in the two 
localities mainly for gold mining for Dangassa and for 
herding or for trading for Nioro-du-Sahel. In both locali-
ties, malaria control strategies rely on the use of long-
lasting insecticide-impregnated nets (LLINs), ACT for 
treatment and sulfadoxine-pyrimethamine (SP) for inter-
mittent preventive treatment of pregnant women (IPTp). 
In addition, the population may have access to other 
malaria drugs in the local market in the two localities.
Study design and sample collection
The study has been set up by the research team in collab-
oration with the local health staff for the entire malaria 
transmission season (June to December 2016). A medi-
cal team was installed at the health centre of the village. 
Population of all age group was encouraged to attend the 
local health centre if febrile, where they were examined 
by a study physician. Malaria cases were diagnosed by a 
rapid diagnostic test (RDT) [CareStart™: Malaria HRP2/
pLDH(Pf/PAN) Combo] and/or microscopy. A four (4) 
ml venous blood was obtained from each TDR positive 
patient. A dried blood spot (DBS) was made by drop-
ping approximatively 50 μl of the venous blood on a filter 
paper. The DNA was extract from the DBS and used for P. 
falciparum genomic and host genetic studies. Confirmed 
malaria cases were classified as mild or severe according 
to the World Health Organization (WHO) definitions 
[36], and treated according to the Malian NMCP guide-
lines (oral ACT for uncomplicated malaria, intramuscu-
lar (i.m) administration of artemether and/or quinine for 
severe malaria).
DNA extraction, sample processing, and genotyping
The dried blood spots on filter paper were sent to the 
Wellcome Sanger Institute for processing. DNA extrac-
tion was carried out using the Qiagen DNA Investigator 
Kit (No. 56504, Qiagen, Crawley, UK) for high-through-
put robotic processing. DNA was eluted in 100 μl TE 
buffer and stored at − 20  °C for later use. Extracted 
DNA underwent whole genome amplification (WGA) 
by primer-extension pre-amplification [37] or selective 
WGA [38] prior to genotyping. Genotyping was per-
formed according to manufacturer’s instruction on the 
Agena MassARRAY ® iPLEX platform (Agena Biosci-
ence, Hamburg, Germany). This system is able to accu-
rately genotype large numbers of samples for multiple 
SNPs simultaneously. It previously been used in P. falci-
parum for sequencing validation of novel SNPs [39]. All 
genotypes were called from background adjusted peak 
intensities, which were normalized and called by batch. 
In brief, batches underwent calling using a heuristic 
algorithm which identifies intensity ranges for each SNP 
in single infection samples, and called mixed base loci 
(“heterozygous”) based on those range thresholds, adjust-
ing for background intensity. Batches were plate based 
and contained between 96 and 384 samples. These are 
necessary to generate per assay ranges of intensities to 
calculate background intensity levels.
Parasite diversity and multiple infection assessment
The malaria parasite diversity and multiplicity of infec-
tion were assessed using the Sanger’s P. falciparum bar-
codes formed by concatenated genotypes at 101 SNPs 
across P. falciparum genome. These SNPs are all bi-allelic, 
at low to medium frequency in global parasite popula-
tions, and were chosen for their usefulness in analyses of 
relationship between P. falciparum parasites. They have 
been used previously to estimate levels of relationship 
and importation [40] as well as complexity of infection. 
Multiplicity of infection estimates were produced by both 
the programmes COIL [41] using default parameters and 
The Real McCOIL [42] using the bi-allelic SNP barcodes.
Drug resistance markers assessment
Specific mutations in P. falciparum genome were 
screened using the Agena MassARRAY ® iPLEX plat-
form as above. The following codons in the P. falciparum 
genome were screened for substitution: K76, N326, I356 
in the Pfcrt gene, the N86, Y184, D1246 in the Pfmdr1 
gene, the N51, C59, S108, I164 in the Pfdhfr gene, the 
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S436, A337, K540, A581, A613 in Pfdhps V127, D128 in 
the Pfarps10 gene, the D193 in Pf-ferredoxin gene, the 
E415 in Pf-exonuclease gene, and T484 in Pfmdr2. Single 
isolate mutations or combination of mutations in these 
codons are associated with resistance to anti-malarial 
drugs as specified in the background section.
Statistical analysis
This was an inclusive study. All the confirmed malaria 
case detected during the study period in the two sites 
were enrolled. A Chi square test was used to compare the 
prevalence of molecular markers in the two study sites. 
When the effective ≥ 30, the Z-test was considered. The 
significant P value was set as equal or inferior to 0.05.
For the Real McCOIL determination, the categori-
cal method was used with the following parameters, 
maxCOI = 25, threshold_ind = 20, threshold_site = 20, 
totalrun = 10,000, burnin = 1000, M0 = 15, e1 = 0.05, 
e2 = 0.05, err_method = 1. Principal component analysis 
was performed to assess and compare the parasite diver-
sity between the two study sites.
Results
In total, 270 P. falciparum samples (214 from Dangassa 
and 56 from Nioro-du-Sahel) were analysed. The analy-
sis of anti-malarial drug genes showed very high rates 
of mutations. The chloroquine-resistance Pfcrt-76T 
genotype was significantly more prevalent in Dangassa 
[64.4% (45.9% 76T + 18.4% 76K/76T)] compared to 
Nioro-du-Sahel [45.2% (37.7% 76T + 7.5% 76K/76T)] 
(p = 0.025) (Fig. 1). This study revealed a very high but 
similar rate of codon-substitution in the pyrimeth-
amine-resistance Pfdhfr gene at positions 51, 59, 108 
and 164 in both Dangassa and Nioro-du-Sahel (Fig.  2) 
(p = 0.2). Respectively, 88.3% and 80% of the isolates 
from Dangassa and Nioro showed at least one substi-
tution at these codons. However the prevalence of the 
particular pyrimethamine-resistance Pfdhfr_51I-19R-
108N genotype reached 14.1% and 19.6% in Dangassa 
and Nioro-du-Sahel, respectively. Higher rate of codon 
substitution was observed in the sulfadoxine-resistance 
Pfdhps gene at positions 436, 437, 540, 581 and 613. 
These substitutions were more prevalent in Dangassa 
as compared to Nioro-du-Sahel (p value = 0.035). Up to 
17.8% of the isolates from Dangassa against 7% for the 
isolates from Nioro-du-Sahel accumulated at least two 
(2) codon-substitutions were detected at these codons 
(Fig. 3).
The particular sulfadoxine-resistance haplotype 
Pfdhps_437G-540E was found in four isolates from Dan-
gassa out of which only one exhibits the pyrimethamine-
resistance Pfdhfr_51I-19R-108N genotype (the quintuple 
Pfdhps_437G-540E/Pfdhfr_51I-19R-108N substitution).
The amodiaquine-resistance Pfmdr1-N86Y muta-
tion was identified in 14.9% (6% Pfmdr1-Y86 + 8.8% 
Pfmdr1-N86/Y86) and 14.2% (8.9% Pfmdr1-Y86 + 8.3% 
Pfmdr1-N86/Y86) of the samples from Dangassa and 
Nioro-du-Sahel, respectively.
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More importantly, the lumefantrine-reduced suscep-
tibility Pfmdr1_184F mutation was found in 39.9% and 
48.2% of samples from Dangassa and Nioro-du-Sahel, 
respectively. Only two (2) isolates from Dangassa exhib-
ited the piperaquine-resistance Exo-E415G mutation. 
Such mutation was not found in Nioro. No artemisinins-
resistance PGB was detected in the genotyped isolates. 
However, isolated codon substitutions constitutive of 
the artemisinin resistance PGB were found. Further 
information regarding the codon variation in studied 
genes is available in Additional file 1: Table S1.
A principal component analysis of genotyping data 
from the Sanger 101 SNPs barcode showed very high 
P. falciparum genomic diversity in both Dangassa and 
Nioro-du-Sahel. However, no aggregation of specific P. 
falciparum genotype was found either in Dangassa or 
in Nioro (Fig.  4). Higher proportion of multiplicity of 
infection was observed in Dangassa using either COIL 
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(p = 0.04) or Real McCOIL (p = 0.02) method based on 
the Sanger 101 SNPs barcode (Table 1).
Discussion
To protect the artemisinin molecules from resistance 
emergence in Africa and delay the spread of this resist-
ance in the world, the WHO recommended ACT for 
uncomplicated malaria treatment in 2001 [4]. Such a 
strategy requires monitoring P. falciparum resistance to 
anti-malarial drugs in different geographical areas and 
adapting the appropriate drug combination. Moreover, 
the monitoring of the malaria parasite genetic varia-
tion will help to predict the dynamic of spread of the 
drug resistance through varying geographical areas. To 
assess molecular markers of anti-malarial drugs resist-
ance and the genetic diversity in P. falciparum circu-
lating isolates through the Malian territory, a passive 
case detection study was carried out in Dangassa and 
Nioro, two distinct epidemiological and eco-climatic 
zones in Mali. The revealed a high prevalence of the 
chloroquine resistance Pfcrt_76T in both localities. 
The Pfcrt_76T mutation was found in 64.3% in Dan-
gassa and 42.5% in Nioro-du-Sahel. This is the first data 
report of anti-malarial drug resistance marker in Nioro, 
but a previous study has reported the prevalence of the 
chloroquine-resistance Pfcrt_76T mutation was of 85% 
in 2002 and 64.5% in 2003 in Kollé, a village sharing 
the same geographical area with Dangassa [31]. These 
observations suggest no decrease in the prevalence of 
chloroquine resistance marker in this region from 2002 
to 2016 despite the official removal of chloroquine 
by the Malian NMCP since the years 2000s. Several 
studies in countries where chloroquine was removed 
reported substantial decrease in the prevalence of the 
chloroquine resistance marker suggesting a possible 
future reintroduction of this low-cost drug [43–46].
The data from this study revealed a very low preva-
lence of amodiaquine resistance-associated mutation 
Pfmdr1_86Y mutant parasite (two (2/214) in Dangassa 
and one (1/56) in Nioro-du-Sahel). The Pfmdr1_86Y 
mutation has been associated with amodiaquine resist-
ance in Burkina Faso [47]. The Pfmdr_86Y mutant iso-
lates was reported at the prevalence of 49.3% in Kolle, 
in 2002; however, the authors could not find association 
between this mutation and amodiaquine resistance in an 
in vivo assay [31]. Amodiaquine is one of most used anti-
malarial drugs in Mali; it is associated with artemisinin 
in ACT and is also used in association with the SP in sea-
sonal malaria control strategy (SMC) in children under 
five (5) years old in Mali.
Surprisingly, a high prevalence of Pfmdr1_Y184F, the 
lumefantrine-reduced susceptibility mutation was found 
in both Dangassa (39.9%) and Nioro-du-Sahel (48.2%). A 
higher prevalence of this mutation (53.8%) was reported 
in Senegal in 2013–2014 [48]. This finding was intrigu-
ing since lumefantrine has never been made available as 
a monotherapy in Mali. Lumefantrine has always been 
administrated in combination with artemether. Two pos-
sible scenarios may explain this finding. First, P. falcipa-
rum is less susceptible to the lumefantrine. This could 
impede on the efficacy of artemisinin-based strategy 
since artemether–lumefantrine is the most used ACT in 
Mali. Second, the Pfmdr1_Y184F mutation is not a good 
lumefantrine-resistance marker in Mali. Although several 
studies have reported an association between Pfmdr1_
Y184F mutation and ex  vivo reduced susceptibility to 
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Fig. 4 Plot Visualization of dot from Principal Component (PC) 
analysis of the 101 SNPs constitutive of barcode. This plot shows 
a wide distribution of the samples from both Dangassa and 
Nioro-du-sahel, with no aggregation of the dots
Table 1 Multiplicity of  infection in  Dangassa and  Nioro-
du-Sahel patients, either  with  the MOI-COIL or  the  MOI-
McCOIL
Index 
of multiplicity 
of infection
Dangassa 
(n = 214)
Nioro-du-
sahel (n = 56)
Difference p
MOI-COIL
 1 139 65.3 44 83.0
 2 73 34.3 9 17.0
 3 1 0.5 0 0.0 0.043
MOI-McCOIL
 1 151 70.9 47 88.7
 2 61 28.6 6 11.3
 3 1 0.5 0 0.0 0.029
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lumefantrine [49, 50], another in  vivo studies could not 
establish this association [51]. Further in vitro investiga-
tions are needed to tease this observation apart.
The codon substitutions were assessed in the Pfdhfr 
and Pfdhp genes to identify SP resistant parasites, char-
acterized by the inheritance of the Pfdhfr_51R-59N-
108I/Pfdhps_437G-540E quintuple mutation. A high level 
of codon substitution was observed in these genes. The 
pyrimethamine-resistance Pfdhfr_51R-59N-108I geno-
type was found in 14.1% in Dangassa and 19.6% in Nioro-
du-Sahel suggesting a decrease in the prevalence of this 
haplotype in the south of Mali as compared to the preva-
lence’s of 31.5% and 42.9% reported respectively 2002 and 
2003 in Kolle [31]. The sulfadoxine resistance haplotype 
Pfdhps_437G-540E was found in only four isolates in 
Dangassa. Only one isolate presented the Pfdhfr_51R-
59N-108I/Pfdhps_437G-540E quintuple substitution in 
Dangassa. SP is widely used in Mali for pregnant woman 
malaria chemoprophylaxis and seasonal malaria chemo-
prophylaxis in children under 5 years old. The data from 
this study suggest that the use of SP is still relevant in 
Mali, but previous reports suggest that such a malaria 
control strategy appears to increase the prevalence of SP-
resistant parasite in Mali [32]. A very high rate of codon 
substitution was observed in these two genes (Pfdhfr and 
Pfdhps)  in both Dangassa and Nioro-du-Sahel (Addi-
tional file 2).
No Pfarps10_127M-128Y/H-Pffd_193Y-Pfcrt_326S-
356T-Pfmdr2_484I artemisinin resistance genetic back-
ground genotype was found during this study. Several 
mutations in P. falciparum kelch 13 protein propel-
ler domain have been associated to resistance to arte-
misinins in Asia [28–30]. A genome wide association 
study revealed that these mutations always arise on the 
above specific genetic background [27]. Even though, 
no artemisinin resistance has been reported yet in Mali, 
[5, 52], a close monitoring for artemisinin resistance is 
essential. Further analysis of individual mutation consti-
tutive of artemisinin resistance genetic background geno-
type may provide appropriate tool to predict artemisinin 
resistance emergence in Africa, where mutation in the 
Pfkelch13 propeller domain were not associated with 
artemisinin resistance [53].
P. falciparum genetic diversity is correlated with the 
level of transmission in different continental regions 
[54–56], and is influenced within regions by factors such 
as altitude, vector availability, urbanization, and malaria 
control strategies [57, 58]. In this study, it was hypoth-
esized that the eco-climatic difference determines the 
malaria transmission variability between the two sites, 
and would impact the fitness of malaria parasites. There-
fore, specific genetic variant of parasites could be selected 
in each site. Using the Sanger’s P. falciparum barcodes 
formed by concatenated genotypes at 101 SNPs across 
P. falciparum genome, the genetic diversity in P. falcipa-
rum circulating isolates was assessed in the study locali-
ties. These genotyping data showed a very high genetic 
diversity in P. falciparum isolates in both Dangassa and 
Nioro-du-Sahel supporting previous finding in Africa, 
even though those studies explored the msp1, msp2 or 
glurp genes size polymorphisms [59, 60]. No aggregation 
of specific P. falciparum genotype was observed at either 
study site. This finding may be due to the fact that the two 
sites are not geographically isolated. A higher complexity 
of P. falciparum infection was found in Dangassa, com-
pared to Nioro-du-Sahel. These findings reflect the dif-
ference of transmission intensity between the two study 
sites. The complexity of infection is known to be associ-
ated with the intensity of malaria transmission [61, 62].
Conclusions
This study revealed high diversity in P. falciparum circu-
lating isolates in Mali. However no genetic population 
structure was found in either low or high transmission 
areas. No artemisinin resistance genetic background was 
found, but high prevalence of the lumefantrine resist-
ance marker (Pfmdr1_Y184F genotype), the most used 
associated molecule to artemisinin in Mali, was detected. 
Further investigations are required to explore the lume-
fantrine resistance in Mali.
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